171 related articles for article (PubMed ID: 22864959)
1. Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer.
Dhar DK; Olde Damink SW; Brindley JH; Godfrey A; Chapman MH; Sandanayake NS; Andreola F; Mazurek S; Hasan T; Malago M; Pereira SP
Cancer; 2013 Feb; 119(3):575-85. PubMed ID: 22864959
[TBL] [Abstract][Full Text] [Related]
2. The Diagnostic Value of Pyruvate Kinase Isoenzyme Type M2 for Biliary Tract Carcinoma. A Systematic Review and Meta-Analysis.
Wang WQ; Liu W; Zhang N; Wang PH; Cao JZ; Chen JM; Li BL; He XD
J Gastrointestin Liver Dis; 2018 Mar; 27(1):73-81. PubMed ID: 29557418
[TBL] [Abstract][Full Text] [Related]
3. MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer.
Matull WR; Andreola F; Loh A; Adiguzel Z; Deheragoda M; Qureshi U; Batra SK; Swallow DM; Pereira SP
Br J Cancer; 2008 May; 98(10):1675-81. PubMed ID: 18475301
[TBL] [Abstract][Full Text] [Related]
4. Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
Shoda J; Matsuda A; Shida T; Yamamoto M; Nagino M; Tsuyuguchi T; Yasaka T; Tazuma S; Uchiyama K; Unno M; Ohkohchi N; Nakanuma Y; Kuno A; Narimatsu H
J Gastroenterol; 2017 Feb; 52(2):218-228. PubMed ID: 27358229
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of pyruvate kinase M2 in bile, serum carbohydrate antigen 19-9, and biliary brushings in diagnosing malignant biliary strictures.
Navaneethan U; Lourdusamy V; Poptic E; Hammel JP; Sanaka MR; Parsi MA
Dig Dis Sci; 2015 Apr; 60(4):903-9. PubMed ID: 25344422
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer].
Kim CW; Kim JI; Park SH; Han JY; Kim JK; Chung KW; Sun HS
Korean J Gastroenterol; 2003 Nov; 42(5):387-93. PubMed ID: 14646575
[TBL] [Abstract][Full Text] [Related]
7. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
Ugurel S; Bell N; Sucker A; Zimpfer A; Rittgen W; Schadendorf D
Int J Cancer; 2005 Dec; 117(5):825-30. PubMed ID: 15957165
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer.
Bandara IA; Baltatzis M; Sanyal S; Siriwardena AK
World J Surg Oncol; 2018 Mar; 16(1):56. PubMed ID: 29540198
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
Goonetilleke KS; Mason JM; Siriwardana P; King NK; France MW; Siriwardena AK
Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054
[TBL] [Abstract][Full Text] [Related]
10. Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract cancer.
Jo JH; Park SB; Chung J; Oh T; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Jung DE; Song SY
BMC Cancer; 2024 Mar; 24(1):357. PubMed ID: 38509504
[TBL] [Abstract][Full Text] [Related]
11. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer.
Shigehara K; Yokomuro S; Ishibashi O; Mizuguchi Y; Arima Y; Kawahigashi Y; Kanda T; Akagi I; Tajiri T; Yoshida H; Takizawa T; Uchida E
PLoS One; 2011; 6(8):e23584. PubMed ID: 21858175
[TBL] [Abstract][Full Text] [Related]
12. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
[TBL] [Abstract][Full Text] [Related]
13. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
14. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy.
Hathurusinghe HR; Goonetilleke KS; Siriwardena AK
Ann Surg Oncol; 2007 Oct; 14(10):2714-20. PubMed ID: 17602267
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients.
Fatela-Cantillo D; Fernandez-Suarez A; Moreno MA; Gutierrez JJ; Iglesias JM
Tumour Biol; 2012 Jun; 33(3):825-32. PubMed ID: 22231432
[TBL] [Abstract][Full Text] [Related]
16. Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer.
Kitamura T; Srivastava J; DiGiovanni J; Kiguchi K
Mol Carcinog; 2015 Jun; 54(6):459-72. PubMed ID: 24839254
[TBL] [Abstract][Full Text] [Related]
17. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Nov; 39(6):554-6. PubMed ID: 11138278
[TBL] [Abstract][Full Text] [Related]
18. Enzyme Kinetic Assay to Measure the Activity of Tumor M2 Pyruvate Kinase in Breast Cancer Patients.
Guan M; Tong Y; Liu X; Dong D; Zhou Y
Ann Clin Lab Sci; 2017 Nov; 47(6):676-686. PubMed ID: 29263041
[TBL] [Abstract][Full Text] [Related]
19. The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
Mayr C; Helm K; Jakab M; Ritter M; Shrestha R; Makaju R; Wagner A; Pichler M; Beyreis M; Staettner S; Jaeger T; Klieser E; Kiesslich T; Neureiter D
Hum Pathol; 2018 Feb; 72():117-126. PubMed ID: 29133140
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
